<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref-47">
 <label>Rosebeck etÂ al. (2016)</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rosebeck</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Alonge</surname>
    <given-names>MM</given-names>
   </name>
   <name>
    <surname>Kandarpa</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Mayampurath</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Volchenboum</surname>
    <given-names>SL</given-names>
   </name>
   <name>
    <surname>Jasielec</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Dytfeld</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Maxwell</surname>
    <given-names>SP</given-names>
   </name>
   <name>
    <surname>Kraftson</surname>
    <given-names>SJ</given-names>
   </name>
   <name>
    <surname>McCauley</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Shacham</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Kauffman</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Jakubowiak</surname>
    <given-names>AJ</given-names>
   </name>
  </person-group>
  <year>2016</year>
  <article-title>Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by Carfilzomib and Selinexor</article-title>
  <source>Molecular Cancer Therapeutics</source>
  <volume>15</volume>
  <issue>1</issue>
  <fpage>60</fpage>
  <lpage>71</lpage>
  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0488</pub-id>
  <pub-id pub-id-type="pmid">26637366</pub-id>
 </element-citation>
</ref>
